Clinical Trials · NCT01642186
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Enrollment
- 28
- Start date
- Jul 2012
- Locations
- 6 sites, United States
- Primary endpoint
- Efficacy Endpoints for Part 1 of the Study is Progression-free Survival at 6 Months (PFS6)